Patients with moderately to severely active ulcerative colitis have an increasing number of advanced therapy options including several biologics and Janus kinase inhibitors. Though data on efficacy and safety of these advanced therapies are available, less is known about the potential economic implications of their utilization in Japan. We evaluated the relative value of these advanced therapies in Japan using a locally developed cost per responder model. A model was developed using relevant clinical endpoints and treatment costs to calculate cost per responder of all advanced therapies used for moderately to severely active ulcerative colitis treatment in Japan. Cost per responder was assessed in biologic-naïve and biologic-exposed populations, respectively. The model incorporated induction and maintenance therapy pathways as patients progressed through based on efficacy rates (clinical response, clinical remission and endoscopic improvement). Total costs for induction and maintenance included: drug acquisition, drug administration and serious adverse event management (as necessary) for responders, with additional rescue treatment cost only for non-responders. Upadacitinib showed lower cost per clinical response and cost per clinical remission across both biologic-naïve and biologic-exposed populations with only one exemption in cost per clinical remission in biologic-naïve population. In addition, upadacitinib demonstrated lower cost per endoscopic improvement in both populations. Janus kinase inhibitors outperformed with lower cost per responder than other mediations across all outcomes and patient populations with the exception of tofacitinib in the clinical remission in biologic-exposed UC population. Comparative data used in this analysis have been derived from network meta-analysis, not from direct comparison. The results of this cost per responder analysis suggest upadacitinib is a cost-effective option for the first- and second-line treatment of moderately to severely active ulcerative colitis in Japan.
For foreign-born populations, difficulty in finding health care information in their primary language is a structural barrier to accessing timely health care. While such information may be available at a national level, it may not always be relevant or appropriate to the living situations of these people. Our objective was to explore the quality of online multilingual health information environments by pilot-testing a framework for assessing such information at the prefectural level in Japan. The framework consisted of five health care domains (health system, hospitals, emergency services, medical interpreters, and health insurance). Framework scores varied considerably among prefectures; many resources were machine-translated. These scores were significantly associated with foreign population proportion and the number of hospitals in each prefecture. Our multilingual health care information environment (MHCIE) framework provides a measure of health access inclusivity, which has not been quantified before. It is adaptable to other international contexts, but further validation is required.
• Inclusion of migrants in public health policy in Japan is rare. • We synthesized the evidence on migrant inclusion during COVID-19. • Vulnerability derived from movement restrictions and socioeconomic background. • Access to support programs was conceptually equal, yet structurally inequitable. • Structural gaps were bridged with social support from host society.
20 January 2015 in BJOG: An International Journal of Obstetrics & Gynaecology
ENEunice Kennedy Shriver National Institute of Child Health and Human Development Maternal‐Fetal Medicine Units (MFMU) Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal‐Fetal Medicine Units (MFMU) Network
+10
Objective: To determine whether β2‐adrenoceptor (β2AR) genotype is associated with shortening of the cervix or with preterm birth (PTB) risk among women with a short cervix in the second trimester.Design: A case–control ancillary study to a multicentre randomised controlled trial.Setting: Fourteen participating centres of the Maternal‐Fetal Medicine Units Network of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.Population: Four hundred thirty‐nine women, including 315 with short cervix and 124 with normal cervical length.Methods: Nulliparous women with cervical length <30 mm upon a 16–22‐week transvaginal sonogram and controls frequency‐matched for race/ethnicity with cervical lengths ≥40 mm were studied. β2AR genotype was determined at positions encoding for amino acid residues 16 and 27.Main outcome measures: Genotype distributions were compared between case and control groups. Within the short cervix group, pregnancy outcomes were compared by genotype, with a primary outcome of PTB <37 weeks.Results: Genotype data were available at position 16 for 433 women and at position 27 for 437. Using a recessive model testing for association between short cervix and genotype, and adjusted for ethnicity, there was no statistical difference between cases and controls for Arg16 homozygosity (OR 0.7, 95% CI 0.4–1.3) or Gln27 homozygosity (OR 0.9, 95% CI 0.3–2.7). Among cases, Arg16 homozygosity was not associated with protection from PTB or spontaneous PTB. Gln27 homozygosity was not associated with PTB risk, although sample size was limited.Conclusions: β2AR genotype does not seem to be associated with short cervical length or with PTB following the second‐trimester identification of a short cervix. Influences on PTB associated with β2AR genotype do not appear to involve a short cervix pathway.
1 August 2020 in American Journal of Obstetrics & Gynecology MFM